Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology
Amsterdam, The Netherlands, Basel, Switzerland and Ingelheim, Germany, (9 January 2025) — Boehringer Ingelheim and Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN) focused on commercializing its clinical-stage platform technology for the development of best-in-class antibody-drug conjugates (ADCs), today announced that Boehringer has licensed Synaffix’s ADC technology. This new partnership significantly bolsters Boehringer’s ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer.
